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Background. The aim of this study was to assess the prevalence, incidence rate (IR), predisposing factors, survival rate, and 
diagnostic delay of progressive multifocal leukoencephalopathy (PML) across medical specialties. Another objective was to survey 
how PML diagnosis was made in the studied cases.
Methods. This is a cross-sectional retrospective observational study of PML cases across different medical specialties during 
2004–2016 in the Finnish Capital Region and Southern Finland. Data were obtained from clinical records, clinical microbiology, 
pathology and radiology department records, and human immunodeficiency virus (HIV) quality register medical records.
Results. A total of 31 patients were diagnosed with PML. The prevalence of PML was 1.56 per 100 000 people and the IR was 
0.12 per 100 000 individuals per year during 2004–2016. Hematologic malignancies (n = 19) and HIV/acquired immune deficiency 
syndrome (n = 5) were the most common underlying diseases, and all patients who had malignant diseases had received cancer 
treatment. Before PML diagnosis, 21 (67.7%) patients were treated with chemotherapy, 14 (45.2%) patients with rituximab, and 1 
patient (3.2%) with natalizumab. Two patients (6.5%) had no obvious immunocompromising disease or treatment. Neither gender, 
age, first symptoms, previous medication, nor underlying disease influenced the survival of PML patients significantly. The 5-year 
survival rate was poor, at less than 10%.
Conclusions. The majority of PML patients in our study had a predisposing disease or had immunosuppressive or monoclonal 
antibody therapy. In the future, broader use of immunosuppressive and immunomodulatory medications may increase incidence 
of PML among patients with diseases unassociated with PML. Safety screening protocols for John Cunningham virus and PML are 
important to prevent new PML cases.
Keywords. HIV; JC virus; monoclonal antibodies; progressive multifocal leukoencephalopathy; rituximab.
Progressive multifocal leukoencephalopathy (PML) is a demye-
linating disease of the central nervous system (CNS) caused by 
John Cunningham (JC) polyomavirus. John Cunningham virus 
(JCV) is a common and normally harmless human virus that 
establishes a life-long persistent infection in the renal tissue [1]. 
Progressive multifocal leukoencephalopathy occurs in immu-
nocompromised individuals, as in acquired immune deficiency 
syndrome (AIDS) patients, and is seen in patients treated with 
immunomodulatory medications for chronic inflammatory 
and autoimmune disorders, hematological malignancies, or 
organ transplant recipients [2]. It is a rare side effect of mono-
clonal antibodies (mAbs) (such as natalizumab and rituximab) 
and other immunosuppressive medicines. The prevalence 
of PML in the general population was estimated at 0.22 per 
100 000 individuals [3]. In a recent Swedish study, the incidence 
was 0.11 per 100 000 individuals per year [4]. In patients with 
autoimmune diseases rates of PML per 100 000 patients for sys-
temic lupus erythematosus (SLE), rheumatoid arthritis (RA), 
and other connective tissue diseases, the incidence was 4.0, 0.4, 
and 2.0, respectively, compared with a rate of PML in the back-
ground population of 0.2 per 100  000 discharges. Rituximab 
therapy was associated with an increased prevalence of PML in 
RA patients (4 per 100 000). In patients with lupus, the risk of 
PML was higher than in RA [5].
Before the AIDS epidemic in the 1980s, PML was a rare dis-
ease. Interest in PML increased among neurologists in 2005 
when its association with natalizumab was discovered [6]. 
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active relapsing-remitting multiple sclerosis (MS). Other 
monoclonal therapies and drugs have also been reported to 
be correlated with an increased risk of PML [7]. Currently, 
MS patients who receive immunomodulatory therapies have 
become the third largest population of PML, after patients 
with human immunodeficiency virus (HIV) and hematological 
malignancies [8]. Respectively, the incidence of PML in HIV-
infected patients has declined in the combined antiretroviral 
therapy era [9].
Among the HIV-infected patients, the known risk factor for 
development of PML is when CD4+ lymphocyte cell counts are 
less than 200 cells/µL [10]. Risk factors for HIV-negative per-
sons have not been reported except for MS patients who receive 
immunomodulatory therapies. Natalizumab-treated MS pa-
tient PML risk has increased by presence of 3 risk factors: pres-
ence of anti-JC virus-antibodies in serum, treatment duration 
over 24 months, and prior treatment with immunosuppressant 
[11]. No particular duration or type of prior immunosuppres-
sant use has been identified as a risk factor. Anti-JCV antibody 
levels in serum or plasma, measured as an index, further helps 
asses PML risk in JCV antibody-positive MS patients who re-
ceive natalizumab treatment [12]. On the other hand, JCV anti-
body-negative MS patients are unlikely to develop PML and 
can be treated with natalizumab for years if a safety protocol 
is followed.
We conducted a descriptive retrospective observational study 
of all incident cases of PML across different medical special-
ties during 2004–2016 in Helsinki University Central Hospital 
(HUCH) region, which covers the Finnish Capital Region and 
Southern Finland. The purpose of this study was to investigate 
the prevalence, incidence rate (IR), predisposing factors, and 
survival of PML. Another objective was to identify the cor-
relates of the symptom-to-diagnosis interval (SDI) (diagnostic 
delay). The third objective was to survey how the PML diag-
nosis was made in the studied cases.
METHODS
Study Participants and Measures
The data were obtained from HUCH clinical records, clinical 
virology department records, pathology department records, 
radiology department records, and the HIV quality register. 
Patients with a suspected diagnosis of PML were examined by 
a radiologist, a neurologist, and an infectious disease physician 
before confirmation of a PML diagnosis.
Progressive multifocal leukoencephalopathy diagnoses were 
based on the American Academy of Neurology (AAN) recom-
mendation [13]. Diagnoses of PML in the database were clas-
sified into 3 categories: (1) possible by typical neuroradiology 
and clinical findings without virological confirmation of JCV; 
(2) laboratory confirmed when patient had typical neuroradiol-
ogy and clinical findings and JCV deoxyribonucleic acid (DNA) 
was detected in cerebrospinal fluid (CSF) by polymerase chain 
reaction (PCR); (3) definitive when patient had typical neurora-
diology and clinical findings confirmed by histologic examina-
tion of a brain biopsy or autopsy specimen.
The JCV laboratory tests were mostly done in the Helsinki 
University Hospital Laboratory (HUSLAB), with few exceptions: 
6 tests were done in the Karolinska University Laboratory and 
5 tests were performed in the University of Turku Laboratory, 
which is now part of the TYKS Microbiology and Genetics 
Department. In the HUSLAB, quantitative JCV DNA PCR from 
plasma and CSF was performed as previously published [14].
In addition to neurological changes, suspicion of PML has 
to be supported by characteristic magnetic resonance imaging 
(MRI) features. All study patients had a 1.5T MRI scan per-
formed. On T1-weighted images PML lesions are hypointense, 
and on T2-weighted and fluid-attenuated inversion recovery 
images hyperintense compared with normal white matter [15]. 
A rim of high signal on diffusion-weighted imaging (DWI) is 
characteristic. Typically, there is no mass effect. Magnetic res-
onance image findings that are highly indicative of PML have 
multifocal, asymmetric periventricular, and subcortical lesions 
with a predilection for the parieto-occipital regions. The sub-
cortical U-fibers are commonly involved. Corpus callosum may 
also be involved [16]. Usually there is no gadolinium enhance-
ment on MRI, but 15% of patients with HIV-associated PML 
and 40% of natalizumab-associated PML may exhibit gado-
linium enhancement at the time of diagnosis [13].
The SDI was calculated as the time between onset of symp-
toms and establishment of diagnosis usually by examination of 
JCV DNA from CSF samples or brain biopsy samples. The prev-
alence and IR were calculated per 100 000 person-years during 
2004–2016. The IR of PML was calculated using the number 
of enrolled patients and the duration of follow-up (13  years). 
Statistical analysis was performed using SPSS versions 23 and 
24. Due to uneven distribution of study data, statistical analysis 
was performed with non-parametric tests. Descriptive anal-
ysis included median value and range. Differences between 2 
groups were assessed with Mann-Whitney U test. Difference 
between more than 2 groups was assessed with Kruskal-Wallis 
test. Survival duration was determined using Kaplan-Meier ap-
proach. The 5-year survival rate was calculated from the point 
of diagnosis to the end of year 2017. The study protocol was 
approved by research board of the Inflammation Center at the 
Helsinki University Hospital on March 29, 2017.
RESULTS
Descriptive Statistics
This study had a total of 31 patients (N = 31): 17 males (54.8%) 
and 14 females (45.2%). The median age at the time of PML di-
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Progressive Multifocal Leukoencephalopathy Diagnoses
In total, 9 patients (29%) had definitive diagnoses of PML, 19 
patients (61.3%) had laboratory-confirmed diagnoses, and 3 
(9.7%) patients had possible diagnoses (Table 1). Two of the 
patients with possible diagnoses had a negative CSF JCV PCR 
result, and from 1 patient CSF sample was not obtained. Two of 
the possible diagnoses patients had hematological malignancies 
and 1 had HIV. All 3 had typical clinical pictures and radiolog-
ical findings of PML. John Cunningham virus DNA was posi-
tive in 23 patients’ CSF (74.2%) and negative in 4 patients’ CSF 
(12.9%). A CSF sample was not taken in 4 cases (12.9%).
Neuroimaging in Progressive Multifocal Leukoencephalopathy
In our study, there were 21 patients (67.7%) with no gadolinium 
enhancement lesions and 8 patients (25.8%) with enhancing 
lesions. Gadolinium enhancement lesion data were omitted 
from 2 patients. Six patients (19%) had presentation of PML in 
posterior fossa, 2 of them had only cerebellar lesions, and 4 had 
both supra- and infratentorial lesions.
Procedures
Autopsies were performed on 10 patients, and complete neu-
ropathological examinations and confirmations for PML 
diagnoses were done on 9 patients (29%). Brain biopsies were 
performed on 4 patients (12.9%) to obtain PML diagnoses.
Prevalence and Incidence Rate of Progressive Multifocal 
Leukoencephalopathy
There were 30 patients from the Finnish Capital Region and 
the HUCH district during 12 years (Figure 1). One patient was 
consulted from outside the region. The population in this area is 
1 919 254 (December 31, 2015) [17]. The total number of indi-
viduals with the disease divided by 100 000 persons in popula-
tion is 1.56 in the HUCH area during the 13 years of study. The 
IR per year is 0.12 per 100 000 person-years during 2004–2016.
Underlying Diseases
Most of the PML patients had been immunosuppressed due 
to underlying diseases or immunomodulatory therapies. In 
this study, there were 19 patients with hematologic malig-
nancies (61.3%): 8 patients with B-cell lymphomas, 4 patients 
with chronic lymphatic leukemia (CLL), 2 patients with 
Waldenstrom’s macroglobulinemia, 2 myeloma patients, 1 pa-
tient with polycythemia vera, 1 with acute myeloid leukemia, 
and 1 patient with mastocytosis. Most of hematologic malig-
nancies (84.2%) were lymphoid neoplasms. Five patients had 
HIV/AIDS (16.1%), 4 of them with CD4 counts below 200 cells 
per mm3 at PML diagnosis and 1 of them after developing im-
mune reconstitution syndrome 5 months after starting antire-
troviral therapy at CD4 count 384 cells per mm3. Three patients 
had rheumatologic disease (9.7%): 2 SLE and 1 dermatomyo-
sitis. Two patients (6.5%) had underlying neurological disease: 
MS and primary CNS vasculitis. Two patients (6.5%) had no 
obvious immunocompromising disease or treatment (Table 2). 
One of these patients had diabetes mellitus type II and suffered 
from alcoholism.
Immunosuppressive Treatment
Twenty-one (67.7%) patients had received cytostatic treat-
ment before a PML diagnosis, 21 patients (67.7%) were treated 
Table 1. Characteristics of PML Patients
Characteristics Total Definite PML Probable PML Possible PML
Patients, n 31 9 19 3
Sex, M/F 17/14 3/5 12/8 2/1
Underlying disease     
 Hematologic malignanciesa  5 12 2
 HIV/AIDS  1 3 1
 Rheumatologic diseases  1 2 0
 Neurologic diseases  0 2 0
 Previously healthy  1 1 0
Brain biopsy 4 4 0 0
Neuropathologically confirmed PML 8 8 0 0
Brain MRI 31 9 19 3
Monoclonal antibody treatmentb 15 2 12 1
Immunosuppressive treatmentc 25 7 16 2
SDI, mean, days 86, 42 104 86 43
Survival at the end of 2017 5 0 5 0
Abbreviations: AIDS, acquired immune deficiency syndrome; HIV, human immunodeficiency virus; MRI, magnetic resonance imaging; PML, progressive multifocal leukoencephalopathy; 
SDI, symptom-to-diagnosis interval.
aEight patients with B-cell lymphomas, 4 patients with chronic lymphatic leukemia, 2 patients with Waldenstrom’s macroglobulinemia, 2 myeloma patients, 1 patient with polycythemia vera, 
1 with acute myeloid leukemia, and 1 patient with mastocytosis.
bRituximab, natalizumab.
cTwenty-one patients had received cancer chemotherapy. Twenty-one patients were treated with cortisone. Four patients were treated with other immunosuppressants such as methotrex-
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with cortisone, and 4 (12.9%) patients were treated with other 
immunosuppressants such as methotrexate, azathioprine, 
mycophenolic acid, hydroxychloroquine, and cyclosporine. 
Fifteen patients had mAb therapy before PML diagnosis: 1 MS 
patient (3.2%) received natalizumab and 14 patients (45.2%) re-
ceived rituximab (Table 1). Seven patients (50%) who received 
rituximab treatment had B-cell lymphoma, 4 (28.6%) had other 
hematologic malignancies, and 3 (21.4%) had rheumatologic 
disease as an underlying disease. Lymphoma patients and he-
matologic patients had rituximab infusions as part of their che-
motherapy regimen. Three patients (21.4%) had their first PML 
symptoms before the end of rituximab treatment. The mean 
times from last rituximab infusion to PML diagnosis and from 
last infusion to first PML symptoms were 5.86 and 3.07 months, 
respectively. The mean time from first rituximab infusion to 
PML symptoms was 27.2 months, minimum time was 1 month, 
and maximum time was 102 months.
Clinical Course and First Symptoms of Progressive Multifocal 
Leukoencephalopathy
In our study, the first symptoms of PML were shown as cog-
nitive and behavioral changes for 13 patients (41.9%), visual 
disturbances for 11 patients (35.5%), language problems for 8 
patients (25.8%), motor weakness for 6 patients (19.4%), ataxia 
for 6 patients (19.4%), headache for 2 patients (6.5%), and 1 pa-
tient (3.2%) had epileptic seizures, nausea, and vertigo. Some 
patients had more than 1 first symptom.
Symptom Diagnosis Interval 
The SDI mean was 86.42  days and median was 57  days. The 
minimum and maximum times were 17 and 450 days, respec-
tively, and range was 433 days.
Survival
Over the course of this study, 5 patients (16.1%) were alive at 
the end of year 2017 and 26 patients (83.9%) were deceased. The 
surviving patients were as follows: 1 with MS diagnosis, 1 with 
SLE, 2 patients with AIDS, and 1 patient with Waldenstrom’s 
macroglobulinemia. Three patients have survived over 5 years, 
making the 5-year survival rate 9.7%. The minimum time from 
first PML symptoms to death was 49 days, and the maximum 
time was 1784 days, the mean was 233.9, and the median was 
130 days. Nine patients (29%) survived 1 year, and 22 patients 
(71%) died during the first year after a diagnosis of PML was 
made. No statistically significant differences in survival of 
PML were observed between women and men or between age 
groups. The time from first symptoms to PML diagnoses, un-
derlying disease, or previous medication did not influence pa-
tient survival.
DISCUSSION
Our study showed that the prevalence of PML was 1.56 in The 
Finnish Capital Region and Southern Finland during 13 years, 
and the IR per year was 0.12 per 100 000 person-years during 
2004–2016. The results are consistent with the previous 
reports from the multinational population of rheumatological 
Table 2. Underlying Disease
Characteristics Frequency Percent
Hematologic malignancies
 Lymphoid neoplasms 16 51.6
 Myeloid neoplasms 3 9.6
HIV/AIDS 5 16.1
Rheumatologic disease 3 9.6
Neurologic diseases 2 6.5
Others 2 6.5
Total 31 100
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patients with PML and the national incidence of PML in 
Sweden [4, 5].
To develop PML, a patient has to have a predisposing disease, 
such as suppressed cellular immunity, for example HIV infec-
tion or B-cell disease, in addition to the JC virus. Progressive 
multifocal leukoencephalopathy may also be an adverse ef-
fect of immunosuppressive therapy or therapeutic mAb, such 
as natalizumab and rituximab regimens. In our study, half of 
the patients had mAb therapy and 67.7% had chemotherapy. 
Seventy-seven percent of patients had classic predisposing dis-
eases such as hematologic malignancies or HIV/AIDS, and all 
the patients who had malignant diseases had received immuno-
modulatory treatment before PML. Only 2 patients (6.5%) had 
no obvious immunocompromising disease or treatment.
Progressive multifocal leukoencephalopathy is not easy to diag-
nose because at the beginning, the disease may be asymptomatic 
[18] and early symptoms are difficult to recognize and detect, 
because they can be cognitive and behavioral. The symptoms result 
from brain lesions in corresponding areas, such as frontal lobes for 
motor weakness, occipital lobes for visual field deficits, and cere-
bellum for ataxia [19]. Clinical features can vary, but hemiparesis, 
ataxia, gait disturbance, visual deficits, and cognitive changes are 
prevalent with limb weakness being the most common with HIV 
and MS-associated PML [15, 19]. Cognitive and gait disturbances 
and visual deficits are the next most common. In our study, the 
most common first symptoms of PML were cognitive and behav-
ioral changes, which were observed in 42% of cases. The next most 
common were visual disturbances and language problems. Motor 
weakness was only observed in 19% of cases. Some patients had 
more than 1 first symptom. Progressive multifocal leukoencepha-
lopathy first symptoms did not influence the outcome or survival of 
patients covered by our study.
In addition to the neurological symptoms, diagnosis of PML 
has to be supported by characteristic imaging features. Brain 
MRI is a valuable tool for confirming a clinical suspicion of 
PML in addition to laboratory diagnostics. The MRI appear-
ance of PML is single or multifocal white matter lesions with 
involvement of subcortical U-fibers. Progressive multifocal 
leukoencephalopathy lesions typically involve white mat-
ter, but gray matter involvement has also been observed [20]. 
Lesions become large and confluent as the disease progresses. 
Usually there is no mass effect or gadolinium enhancement 
[16]. However, gadolinium enhancement has been observed in 
HIV- and natalizumab-associated PML lesions [15], and it was 
observed in 26% of our cases. The PML may occur anywhere in 
the brain, but the frontal and parieto-occipital regions are most 
commonly affected [15].
According to the AAN recommendations, it is important to 
associate the clinical and imaging abnormalities with the evidence 
of JCV in the brain to make a PML diagnosis [13]. Although JCV 
antibody testing in plasma can be used to assess PML risk, it has 
currently no diagnostic value after the onset of PML. Instead, a 
valuable diagnostic tool is a sensitive laboratory test to detect intra-
thecal JCV DNA in CSF by highly sensitive PCR. Cerebrospinal 
fluid examination also helps to exclude other diagnoses. Despite the 
high sensitivity of PCR, a negative test result does not rule out PML 
[13]. In HIV-infected patients, the viral load in CSF is high and 
sufficient for diagnosis. Acquired immune deficiency syndrome 
treatment decreases viral load and makes laboratory-confirmed 
diagnosis difficult. In addition, in patients with MS and other auto-
immune diseases, the viral loads are low [13]. This creates a need 
to take multiple CSF samples despite a clinically strong suspicion 
of PML because initial samples are falsely negative. In our study, 
JCV DNA was positive in 23 patients’ CSF (74.2%) and negative 
in 4 patients’ CSF (12.9%). Cerebrospinal fluid samples were taken 
once from 16 patients (51.6%), twice from 9 patients (29%), thrice 
from 2 patients (6.5%), and not taken at all in 4 cases (12.9%).
A brain biopsy is indicated in patients where the CSF cannot 
be obtained or is negative and the MRI is not characteristic of 
the disease. Infected brain cells can be demonstrated by immu-
nohistochemistry, in situ hybridization, or PCR analysis [21].
An early PML diagnosis is important especially in natalizum-
ab-treated MS patients, because prompt restoration of the immune 
system is the only intervention that can improve survival chances 
[22]. The median SDI in literature has been reported as 74  days 
(range, 1–1643) [23]. The mean SDI time in our study was 86 days 
and the median time was 57 days (range, 17–450). Two patients with 
a hematological disease had the shortest SDI values (17–21 days). 
Two patients with a rheumatological disease (SLE and dermatomy-
ositis with SDI 450 and 168 days, respectively) and 1 with hemato-
logical disease (SDI 177 days) had the longest SDI values.
Progressive multifocal leukoencephalopathy is a highly 
debilitating disease with a high mortality rate. For most 
patients with existing serious immunosuppressive diseases, 
the detected PML diagnosis leads to death. Within the first 
3 months of diagnosis, the mortality rate is 30%–50% [24]. For 
patients with HIV-associated disease, the 2-year mortality rate 
is 50%–60%, despite highly active antiretroviral therapy and 
adjunctive treatments [25, 26]. Survival of PML patients with 
hematologic malignancies is very poor, with approximately 
90% mortality within 2  months of diagnosis [27]. In PML 
associated with iatrogenic immunosuppression, removal of a 
causative agent together with supportive care has improved 
survival rate up to 77% [22]. Reversal of natalizumab immu-
nosuppression by plasmapheresis to restore immune func-
tion has improved the outcome of MS-associated PML [15]. 
Predictors for favorable outcomes in natalizumab-associated 
PML cases were younger age, lower Expanded Disability 
Status Scale (EDSS) score prior to diagnosis, shorter diagnos-
tic delay, and more localized brain lesion on MRI at the time 
of diagnosis [28]. Our results showed that patient gender, age, 
or underlying disease did not significantly influence the out-
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This study was limited by being single-centered and using an 
observational retrospective method. On the other hand, most 
of the PML diagnoses were made in co-operation between a 
radiologist, a neurologist, a pathologist, and an infectious phy-
sician according to AAN recommendation: 29% had definite 
diagnoses of PML, and 61.3% had laboratory-confirmed PML 
diagnoses. Only 1 diagnosis was made post mortem.
In the future, broader use of immunosuppressive and 
immunomodulatory medications in the fields of rheuma-
tology, neurology, gastroenterology, and dermatology may 
increase incidence of PML among patients with diseases 
unassociated with PML. With a growing number of available 
therapies, patients are multiexposed to different drugs in the 
course of their disease, making it difficult to evaluate individ-
ual patient’s total risk of PML and different medications risk 
of causing PML as a severe side effect. Each treatment-associ-
ated case of PML should be assessed and reported, regardless 
of the patient’s previous medical treatment. The risk-ben-
efit ratio of mAb therapies should be carefully assessed, 
especially if these treatments are used off-label. Progressive 
multifocal leukoencephalopathy risk for MS patients is well 
known, and disease-modifying therapies have been classified 
by their PML risk [29]. For example, natalizumab has high 
PML risk. According to latest Tysabry Safety Update infor-
mation, the global overall incidence of PML in natalizum-
ab-treated patients is 4.15 per 1000 patients (95% CI = 3.87 
to 4.44 per 1000 patients). Much lower risk exists for fin-
golimod and dimethyl fumarate. There are approximately 
9000 MS patients in Finland, 2700 of which receive different 
MS disease-modulating drugs in HUCH. Over an 11-year 
period, there have been approximately 70–80 patients per 
year who receive 1 natalizumab intravenous infusion per 
month, during which only 1 PML case has been recorded in 
the Finnish capital region and Southern Finland. After that 1 
case, we have considerably improved the natalizumab safety 
screening protocol. This has proven to be effective despite 
high costs. There have been no other PML cases among our 
MS patients. For other than MS patients’ treatments, there 
are no such classification and safety protocols. In our study, 
there were 14 patients who had rituximab therapy, 80% of 
which had B-cell lymphomas or hematologic malignancies 
as underlying diseases and 20% had rheumatologic diseases. 
All of these patients were not screened for PML risk. It may 
be argued that this is acceptable in cancer patients because 
rituximab therapy greatly improved likelihood of event-free 
survival, but for rheumatology patients this is questionable.
CONCLUSIONS
All physicians who use mAb treatments should be aware of risks, 
diagnosis, and management of PML. Proper information shar-
ing to both patients and medical staff plays an essential role in 
the prevention, early detection, and risk factor screening. If PML 
risk is acknowledged, preventative actions are required, such as 
switching therapies, regular brain MRI, and symptoms moni-
toring. If new symptoms occur, PML should be considered and 
appropriate diagnostic testing should be done as soon as possible.
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